- Report
- October 2024
- 184 Pages
Global
From €3245EUR$3,545USD£2,758GBP
€3606EUR$3,939USD£3,064GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2746EUR$3,000USD£2,334GBP
- Report
- July 2024
- 150 Pages
Global
From €4074EUR$4,450USD£3,462GBP
- Report
- May 2024
- 132 Pages
Global
From €5949EUR$6,499USD£5,056GBP
- Report
- May 2024
- 131 Pages
Global
From €5949EUR$6,499USD£5,056GBP
- Report
- May 2024
- 132 Pages
Global
From €5949EUR$6,499USD£5,056GBP
- Report
- December 2023
- 140 Pages
Global
From €4074EUR$4,450USD£3,462GBP
- Report
- April 2023
- 180 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Report
- October 2023
- 145 Pages
Global
From €2884EUR$3,150USD£2,451GBP
- Report
- February 2024
- 360 Pages
Global
From €7277EUR$7,950USD£6,185GBP
- Report
- August 2024
- 80 Pages
Japan
From €3204EUR$3,500USD£2,723GBP
- Report
- November 2020
- 199 Pages
Global
€4119EUR$4,500USD£3,501GBP
- Report
- April 2025
- 50 Pages
Global
From €2426EUR$2,650USD£2,062GBP
- Report
- November 2024
- 240 Pages
Global
From €1701EUR$1,859USD£1,446GBP
€2430EUR$2,655USD£2,066GBP

Bimatoprost is a medication used to treat glaucoma and other optical disorders. It is a prostaglandin analog, meaning it works by increasing the outflow of fluid from the eye, reducing intraocular pressure. Bimatoprost is available as a topical ophthalmic solution, and is the only prostaglandin analog approved for the treatment of glaucoma and ocular hypertension. It is also used to treat hypotrichosis, a condition characterized by inadequate or thinning eyelashes.
Bimatoprost is a widely used medication in the optical disorders drugs market. It is the most commonly prescribed prostaglandin analog for glaucoma and ocular hypertension, and is also used off-label for other conditions. Bimatoprost is generally well-tolerated, with few side effects.
Some companies in the Bimatoprost market include Allergan, Sun Pharmaceuticals, and Pfizer. Show Less Read more